Preventive and therapeutic anti-inflammatory effects of systemic and topical thalidomide on endotoxin-induced uveitis in rats

Experimental Eye Research

Volumn 84, Issue 3, 2007, Pages 553-560

  Rodrigues, Gustavo Büchele ^a   Passos, Giselle Fazzioni ^a   Di Giunta, Gabriella ^a   Figueiredo, Cláudia Pinto ^a   Rodrigues, Eduardo Büchele ^b   Grumman Jr , Astor ^b   Medeiros, Rodrigo ^a   Calixto, João B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b Hospital Regional Sao Jose   (Brazil)

Author keywords

cyclooxygenase 2; inducible nitric oxide synthase; inflammation; interleukin 1 ; thalidomide; tumour necrosis factor ; uveitis

Indexed keywords

CYCLOOXYGENASE 2; DEXAMETHASONE; ENDOTOXIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PROTEIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AQUEOUS HUMOR; ARTICLE; CELL COUNT; CELL INFILTRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; EYE PROTECTION; HINDLIMB; IMMUNOMODULATION; INFLAMMATORY CELL; LEUKOCYTE; MALE; NONHUMAN; OUTCOME ASSESSMENT; PREMEDICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA; SYSTEMIC THERAPY; TREATMENT DURATION; UVEITIS;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; AQUEOUS HUMOR; BLOTTING, WESTERN; CYCLOOXYGENASE 2; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE PROTEINS; INTERLEUKIN-1; LEUKOCYTES; LIPOPOLYSACCHARIDES; MALE; MEMBRANE PROTEINS; MODELS, ANIMAL; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, WISTAR; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 33846839487     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2006.11.009     Document Type: Article

References (24)

1. Appleton I., Tomlinson A., and Willoughby D.A. Induction of cyclo-oxygenase and nitric oxide synthase in inflammation. Adv. Pharmacol. 35 (1996) 27-78
2. Baatz H., Tonessen B., Prada J., and Pleyer U. Thalidomide inhibits leukocyte-endothelium interaction in endotoxin-induced uveitis. Ophthalmic Res. 33 (2001) 256-263
3. Beutler B., and Rietschel E.T. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol. 3 (2003) 169-176
4. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91 (1994) 4082-4085
5. de Smet M.D., and Chan C.C. Regulation of ocular inflammation-what experimental and human studies have taught us. Prog. Retin. Eye Res. 20 (2001) 761-797
6. De Vos A.F., Hoekzema R., and Kijlstra A. Cytokines and uveitis, a review. Curr. Eye Res. 11 (1992) 581-597
7. Guex-Crosier Y., Pittet N., and Herbort C.P. The effect of thalidomide and supidimide on endotoxin-induced uveitis in rats. Graefes. Arch. Clin. Exp. Ophthalmol. 233 (1995) 90-93
8. Hales B.F. Thalidomide on the comeback trail. Nat. Med. 5 (1999) 489-490
9. Hoekzema R., Verhagen C., van Haren M., and Kijlstra A. Endotoxin-induced uveitis in the rat. The significance of intraocular interleukin-6. Invest. Ophthalmol. Vis. Sci. 33 (1992) 532-539
10. Moncada S. Nitric oxide: discovery and impact on clinical medicine. J.R. Soc. Med. 92 (1999) 164-169
11. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., and Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 177 (1993) 1675-1680
12. Oliver S.J., Cheng T.P., Banquerigo M.L., and Brahn E. The effect of thalidomide and 2 analogs on collagen induced arthritis. J. Rheumatol. 25 (1998) 964-969
13. Parentin F., Da Pozzo S., Lepore L., and Perissutti P. Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis ina three-year-old child. Ophthalmologica 215 (2001) 70-73
14. Raje N., and Anderson K. Thalidomide-a revival story. N. Engl. J. Med. 341 (1999) 1606-1609
15. Raje M., and Anderson K.C. Thalidomide and immunomodulatory drugs as cancer therapy. Curr. Opin. Oncol. 14 (2002) 635-640
16. Rosenbaum J.T., McDevitt H.O., Guss R.B., and Egbert P.R. Endotoxin-induced uveitis in rats as a model for human disease. Nature 286 (1980) 611-613
17. Ruiz-Moreno J.M., Thillaye B., and de Kozak Y. Retino-choroidal changes in endotoxin-induced uveitis in the rat. Ophthalmic Res. 24 (1992) 162-168
18. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., and Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med. 173 (1991) 699-703
19. Sampaio E.P., Kaplan G., Miranda A., Nery J.A., Miguel C.P., Viana S.M., and Sarno E.N. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 168 (1993) 408-414
20. Shek L.P., and Lim D.L. Thalidomide in Behcet's disease. Biomed. Pharmacother. 56 (2002) 31-35
21. Siefert B., Pleyer U., Muller M., Hartmann C., and Keipert S. Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide. J. Ocul. Pharmacol. Ther. 15 (1999) 429-438
22. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M., Zeddis J., and Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 341 (1999) 1565-1571
23. Turini M.E., and DuBois R.N. Cyclooxygenase-2: a therapeutic target. Annu. Rev. Med. 53 (2002) 35-57
24. Vale M.L., Cunha F.A., Brito G.A., Benevides V.M., Ferreira S.H., Poole S., and Ribeiro R.A. Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation. Eur. J. Pharmacol. 536 (2006) 309-317